Fundacion Of Investigacion Del Hospital Clinico Universitario Of Valencia Fihcuv

Valencia, Spain

Fundacion Of Investigacion Del Hospital Clinico Universitario Of Valencia Fihcuv

Valencia, Spain
SEARCH FILTERS
Time filter
Source Type

PubMed | Fundacion Of Investigacion Del Hospital Clinico Universitario Of Valencia Fihcuv, University of Valencia and University Miguel Hernández
Type: | Journal: Neuropharmacology | Year: 2014

Motoneuron diseases are fatal neurodegenerative disorders characterized by a progressive loss of motoneurons, muscle weakness and premature death. The progressive motor neuronopathy (pmn) mutant mouse has been considered a good model for the autosomal recessive childhood form of spinal muscular atrophy (SMA). Here, we investigated the therapeutic potential of Erythropoietin (Epo) on this mutant mouse. Symptomatic or pre-symptomatic treatment with Epo significantly prolongs lifespan by 84.6% or 87.2% respectively. Epo preserves muscle strength and significantly attenuates behavioural motor deficits of mutant pmn mice. Histological and metabolic changes in the spinal cord evaluated by immunohistochemistry, western blot, and high-resolution (1)H-NMR spectroscopy were also greatly prevented by Epo-treatment. Our results illustrate the efficacy of Epo in improving quality of life of mutant pmn mice and open novel therapeutic pathways for motoneuron diseases.

Loading Fundacion Of Investigacion Del Hospital Clinico Universitario Of Valencia Fihcuv collaborators
Loading Fundacion Of Investigacion Del Hospital Clinico Universitario Of Valencia Fihcuv collaborators